Result card

  • CUR7: What is the target population in this current assessment of intravenous immunoglobulin (IVIG) therapy?
English

What is the target population in this current assessment of intravenous immunoglobulin (IVIG) therapy?

Authors: Antonio Migliore, Tapani Keranen, Sinikka Sihvo

Internal reviewers: Kristian Lampe

Target populations for IVIG therapy are {Appendix SAF-1}:

  • Patients with Mild Cognitive Impairment (ICD-9-CM Diagnosis Code 331.83; ICD-10-CM G31.84) as defined by validated criteria;
  • Patients with mild-to-moderate Alzheimer’s disease (ICD-9-CM Diagnosis Code 331.0; ICD-10-CM G30.9), as defined by validated criteria and with MMSE score between 15 and 26;

Patients with moderate-to-severe Alzheimer’s disease (ICD-9-CM Diagnosis Code 331.0; ICD-10-CM G30.9), as defined by validated criteria and with MMSE score less than or equal to 14.

Critical
Completely
Migliore A et al. Result Card CUR7 In: Migliore A et al. Health Problem and Current Use of the Technology In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 30 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267